UCLA Health

uclahealth.org

For more than half a century, UCLA Health has provided the best in healthcare and the latest in medical technology to the people of Los Angeles and throughout the world. Comprised of Ronald Reagan UCLA Medical Center, UCLA Medical Center Santa Monica, Resnick Neuropsychiatric Hospital at UCLA, UCLA Mattel Children's Hospital, and the UCLA Medical Group with its wide-reaching system of primary-care and specialty-care offices throughout the region, UCLA Health is among the most comprehensive and advanced healthcare systems in the world.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy, Industrial Impact

GENSCRIPT PROBIO ENTERS INTO STRATEGIC PARTNERSHIP WITH RVAC MEDICINES

GenScript ProBio | February 24, 2023

news image

GenScript ProBio, a renowned Contract Development and Manufacturing Organization (CDMO), has recently entered a strategic partnership agreement with RVAC Medicines Pte. Ltd., a biotech company specializing in the development and commercialization of mRNA vaccines and therapeutics. The collaboration is aimed at manufacturing GMP-grade plasmid DNA (pDNA) for the RVM-V001 mRNA COVID-19 vaccine candidate, as well as supporting future therapeutic pipelines. GenScript ProBio will offe...

Read More

Cell and Gene Therapy

SESEN BIO AND CARISMA THERAPEUTICS ANNOUNCE MERGER AGREEMENT

Sesen Bio and Carisma Therapeutics | September 22, 2022

news image

Sesen Bio, Inc. and Carisma Therapeutics Inc. a privately held, clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on the advancement of Carisma’s proprietary cell therapy platform that utilizes engineered macrophages and monocytes to potentially transform the treatment of cancer and...

Read More

Medical

ANIXA BIOSCIENCES ANNOUNCES THE INITIATION OF ITS OVARIAN CANCER CAR-T PHASE 1 TRIAL AT MOFFITT CANCER CENTER

Anixa | March 31, 2022

news image

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced the initiation of a Phase 1 trial evaluating its novel chimeric antigen receptor T-cell (CAR-T) therapy in ovarian cancer. The CAR-T approach used for Anixa's therapy is known as chimeric endocrine receptor T-cell (CER-T) since the target of the engineered T-cells is an endocrine receptor. The Phase 1 trial at Moffitt Cancer Center will ev...

Read More

Research

EVELO BIOSCIENCES PRESENTS DATA ON EDP1815 MECHANISM OF ACTION AND SUPPORTING ONGOING CLINICAL DEVELOPMENT FOR INFLAMMATORY DISEASES

Evelo Biosciences, Inc. | January 18, 2022

news image

Evelo Biosciences, Inc. a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced data for EDP1815, the Company’s lead product in inflammation, detailing its mechanism of action and supporting further clinical development in patients with psoriasis and atopic dermatitis. The data were presented in two posters on Saturday, January 15, 2022, at the 2022 Winter Clinical Dermatology Congr...

Read More
news image

Cell and Gene Therapy, Industrial Impact

GENSCRIPT PROBIO ENTERS INTO STRATEGIC PARTNERSHIP WITH RVAC MEDICINES

GenScript ProBio | February 24, 2023

GenScript ProBio, a renowned Contract Development and Manufacturing Organization (CDMO), has recently entered a strategic partnership agreement with RVAC Medicines Pte. Ltd., a biotech company specializing in the development and commercialization of mRNA vaccines and therapeutics. The collaboration is aimed at manufacturing GMP-grade plasmid DNA (pDNA) for the RVM-V001 mRNA COVID-19 vaccine candidate, as well as supporting future therapeutic pipelines. GenScript ProBio will offe...

Read More
news image

Cell and Gene Therapy

SESEN BIO AND CARISMA THERAPEUTICS ANNOUNCE MERGER AGREEMENT

Sesen Bio and Carisma Therapeutics | September 22, 2022

Sesen Bio, Inc. and Carisma Therapeutics Inc. a privately held, clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on the advancement of Carisma’s proprietary cell therapy platform that utilizes engineered macrophages and monocytes to potentially transform the treatment of cancer and...

Read More
news image

Medical

ANIXA BIOSCIENCES ANNOUNCES THE INITIATION OF ITS OVARIAN CANCER CAR-T PHASE 1 TRIAL AT MOFFITT CANCER CENTER

Anixa | March 31, 2022

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced the initiation of a Phase 1 trial evaluating its novel chimeric antigen receptor T-cell (CAR-T) therapy in ovarian cancer. The CAR-T approach used for Anixa's therapy is known as chimeric endocrine receptor T-cell (CER-T) since the target of the engineered T-cells is an endocrine receptor. The Phase 1 trial at Moffitt Cancer Center will ev...

Read More
news image

Research

EVELO BIOSCIENCES PRESENTS DATA ON EDP1815 MECHANISM OF ACTION AND SUPPORTING ONGOING CLINICAL DEVELOPMENT FOR INFLAMMATORY DISEASES

Evelo Biosciences, Inc. | January 18, 2022

Evelo Biosciences, Inc. a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced data for EDP1815, the Company’s lead product in inflammation, detailing its mechanism of action and supporting further clinical development in patients with psoriasis and atopic dermatitis. The data were presented in two posters on Saturday, January 15, 2022, at the 2022 Winter Clinical Dermatology Congr...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us